Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.00

OnKure Therapeutics, Inc. (NASDAQ:OKUR) has received an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $32.00.

A number of brokerages have issued reports on OKUR. Wall Street Zen upgraded OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

Hedge Funds Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acorn Capital Advisors LLC raised its stake in OnKure Therapeutics by 97.2% during the 2nd quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock worth $6,787,000 after buying an additional 1,400,000 shares during the period. Highbridge Capital Management LLC grew its stake in OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock valued at $1,586,000 after acquiring an additional 224,810 shares during the period. Shay Capital LLC increased its holdings in shares of OnKure Therapeutics by 17.4% in the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after acquiring an additional 135,888 shares in the last quarter. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics during the second quarter worth about $71,000. Finally, Prosight Management LP lifted its holdings in shares of OnKure Therapeutics by 67.8% during the 3rd quarter. Prosight Management LP now owns 267,959 shares of the company’s stock valued at $737,000 after purchasing an additional 108,267 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Stock Performance

OKUR opened at $3.00 on Friday. The company has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $2.76. The firm has a market capitalization of $40.65 million, a PE ratio of -0.63 and a beta of 0.47. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $6.48.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.11. Equities analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.